The efficacy and safety of mizoribine in living donor kidney transplantation: a 24-week, open-label, prospective study (phase III clinical trial).
Cho
D K
DK
The Department of Internal Medicine, Kyungpook University Hospital, Daegu, South Korea.
Kim
J H
JH
Park
S H
SH
Kim
J C
JC
Kim
C D
CD
Baek
M Y
MY
Kim
S J
SJ
Kim
S H
SH
Kwon
T H
TH
Kim
Y L
YL
Kim
Y W
YW
Chang
S K
SK
D001379:Azathioprine / Q000627:therapeutic use; D003404:Creatinine / Q000097:blood; D016572:Cyclosporine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology*; D019520:Living Donors; D011241:Prednisone / Q000627:therapeutic use; D011446:Prospective Studies; D012263:Ribonucleosides / Q000627:therapeutic use*; D012449:Safety
D007166:Immunosuppressive Agents; D012263:Ribonucleosides; C010052:mizoribine; D016572:Cyclosporine; D003404:Creatinine; D001379:Azathioprine; D011241:Prednisone